Skip to content
MarketHOT
中文
← Latest news

6-K - Cardiol Therapeutics Inc. (0001702123) (Filer)

SEC · EDGAR 财务披露 · November 3, 2026 at 5:16 PM ET

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.

(Name of registrant)

602-2265 Upper Middle Road East 

Oakville, Ontario L6H 0G5 

Canada 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

¨ Form 20-F                                     x Form 40-F

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 to this report on Form 6-K are hereby incorporated by reference as Exhibits to the Registration Statement on Form F-10 of Cardiol Therapeutics Inc. (File No. 333-298852), as amended and supplemented.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CARDIOL THERAPEUTICS INC.
  (Registrant)
       
Date:  November 3, 2026 By: /s/ Christopher Waddick
    Name: Christopher Waddick
    Title: Chief Financial Officer

Form 6-K Exhibit Index

Exhibit 
Number
  Document Description
     
99.1   Open Market Sale Agreement, dated November 3, 2026
     
99.2   Consent of Borden Ladner Gervais LLP, dated November 3, 2026

View source ↗ · 中文页面